Abbott Laboratories (ABT) Tops Q3 EPS by 1c; Narrows FY11 EPS Outlook
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Join SI Premium – FREE
Abbott Laboratories (NYSE: ABT) reported Q3 EPS of $1.18, $0.01 better than the analyst estimate of $1.17. Revenue for the quarter came in at $9.82 billion versus the consensus estimate of $9.65 billion.
Abbott Laboratories sees FY2011 EPS of $4.64-$4.66, versus prior guidance of $4.58-$4.68 and the consensus of $4.64.
Abbott Laboratories sees FY2011 EPS of $4.64-$4.66, versus prior guidance of $4.58-$4.68 and the consensus of $4.64.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Abbott Labs (ABT) to Outperform
- Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
- Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
